News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CELLECTIS SA Extends Its TAL Technology Intellectual Property Portfolio Through the Acquisition of Two Exclusive Licenses From Iowa State University



10/25/2012 10:07:40 AM

PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Alternext: ALCLS), the genome engineering specialist, announces that it has signed two exclusive license agreements with the Iowa State University that grant Cellectis the worldwide right to use inventions related to TAL effector-nucleases (TALENsTM) and monomeric TALENsTM.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES